Sarah Cannon | Strategic Alliance Partners

October 25, 2021

Dr. Johnson discusses the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoing phase 2 RAMP 202 trial in KRAS-mutant non–small cell lung cancer, and where the combination could be used in practice pending further positive study results.

October 15, 2021

Melissa L. Johnson, MD, discusses the emergence of datopotamab deruxtecan in non–small cell lung cancer with actionable genomic alterations.

October 13, 2021

Melissa L. Johnson, MD, discusses the promise of DS-7300 in small cell lung cancer and other advanced solid tumors.

October 12, 2021

Erika P. Hamilton, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.

October 11, 2021

Spanning metastatic non–small cell lung cancer, castration-resistant prostate cancer, and HER2-low breast cancer, here are 4 must-know clinical trials in Tennessee that community oncologists can now enroll their patients on.

October 08, 2021

Selective estrogen receptor degraders and antibody-drug conjugates are not only broadening the armamentarium in breast cancer but are demonstrating increasing utility across subtypes and in underserved populations, such as those with HER2-low disease, explained Erika P. Hamilton, MD.

October 06, 2021

October 05, 2021

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the integration of sacituzumab govitecan-hziy into the treatment landscape of metastatic triple-negative breast cancer.

October 04, 2021

Erika P. Hamilton, MD, discusses the potential integration of novel selective estrogen receptor degraders into the treatment armamentarium for ER-positive, HER2-negative breast cancer.

October 04, 2021

Denise A. Yardley, MD, discusses the efficacy achieved with ribociclib plus letrozole in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

October 01, 2021

Rovalpituzumab tesirine failed to show an efficacy or safety benefit as a frontline, maintenance, and second-line treatment for patients with advanced small cell lung cancer, warranting its discontinued development.

September 29, 2021

Sarah Cannon recently opened its newest drug development unit in collaboration with Florida Cancer Specialists & Research Institute and The University of Central Florida College of Medicine in Lake Nona, Flordia.

August 03, 2021

The 2021 ASCO Annual Meeting was chock full of practice-changing, practice-affirming, and exciting preliminary research in non–small cell lung cancer, said Melissa Johnson, MD.

June 24, 2021

Sarah Cannon announced today that Navneet Majhail, MD, MS, FASTCT has been named Deputy Physician-in-Chief of Blood Cancers for the Sarah Cannon Transplant and Cellular Therapy Network.

April 19, 2021

Darovasertib, both as a single agent and in combination with binimetinib, has demonstrated promising early activity in patients with metastatic uveal melanoma, according to preliminary data from an ongoing phase 1/2 trial.

March 11, 2021

Melissa L. Johnson, MD, discusses the implications of recent advances made in the development of oncogenetargeted agents in non–small cell lung cancer.

February 23, 2021

February 23, 2021 - The first patient in a first-in-human phase 1 study has been dosed with DS-6000, a novel CDH6-directed antibody-drug conjugate.

February 16, 2021

Andrew Mckenzie, PhD, discusses the differences between tissue- and plasma-based NGS tests, factors that can lead to a lack of concordance, and important areas of ongoing research.

February 01, 2021

David Spigel, MD, discusses advances in early-stage lung cancer treatment.

February 01, 2021

Andrew McKenzie, PhD, discusses the rationale to utilize concurrent tissue- and liquid-based biopsies in lung cancer.